EZH2: a novel target for cancer treatment
| Autor: | Wenfang Du, Ran Duan, Weijian Guo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research Adenosine H3K27me3 EZH2 inhibitor Review Metastasis Histones 0302 clinical medicine Neoplasms Gene expression Tumor Microenvironment Multicenter Studies as Topic Neoplasm Metastasis Cancer Clinical Trials as Topic biology Cell Cycle EZH2 Polycomb Repressive Complex 2 lcsh:Diseases of the blood and blood-forming organs Hematology lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Combined Modality Therapy Neoplasm Proteins Histone Code Cell Transformation Neoplastic Histone Oncology 030220 oncology & carcinogenesis Benzamides PRC2 Transcriptional Activation Senescence Pyridones Morpholines Antineoplastic Agents macromolecular substances Epigenetic Repression lcsh:RC254-282 Methylation Structure-Activity Relationship 03 medical and health sciences medicine Humans Enhancer of Zeste Homolog 2 Protein Molecular Biology Gene lcsh:RC633-647.5 Biphenyl Compounds medicine.disease 030104 developmental biology Drug Resistance Neoplasm biology.protein Cancer research |
| Zdroj: | Journal of Hematology & Oncology Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2020) |
| ISSN: | 1756-8722 |
| DOI: | 10.1186/s13045-020-00937-8 |
| Popis: | Enhancer of zeste homolog 2 (EZH2) is enzymatic catalytic subunit of polycomb repressive complex 2 (PRC2) that can alter downstream target genes expression by trimethylation of Lys-27 in histone 3 (H3K27me3). EZH2 could also regulate gene expression in ways besides H3K27me3. Functions of EZH2 in cells proliferation, apoptosis, and senescence have been identified. Its important roles in the pathophysiology of cancer are now widely concerned. Therefore, targeting EZH2 for cancer therapy is a hot research topic now and different types of EZH2 inhibitors have been developed. In this review, we summarize the structure and action modes of EZH2, focusing on up-to-date findings regarding the role of EZH2 in cancer initiation, progression, metastasis, metabolism, drug resistance, and immunity regulation. Furtherly, we highlight the advance of targeting EZH2 therapies in experiments and clinical studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink